Sizzling Stock: REGENXBIO Inc. (NASDAQ:RGNX)

Spread the love

REGENXBIO Inc. (NASDAQ:RGNX) changed -0.68% to recent value of $ 65.7. The stock transacted shares during most recent the day were 751949 shares however it has an average volume of 706.70K shares. It spotted trading -22.80% off of the 52-week high price. On the other end, the stock has been noted 237.79% away from the low price over the last 52-weeks.

RGNX has a gross margin of 97.20% as compared to operating margin of -53.30% and its profit margin remained -51.40% for the last 12 months. The company has earnings of $ 53.10M and made $142.30M revenue for the last 12 month. Its earnings per share (EPS) expected to touch remained -2.70% for this year while earning per share for the next 5-years is expected to reach at 4.00%.

REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today declared the closing of its previously announced underwritten public offering of 2,700,000 shares of its common stock at a price to the public of $65.00 per share, as well as the exercise in full of the underwriters’ option to purchase 405,000 additional shares at the public offering price. Including the option exercise, the total gross proceeds to REGENXBIO are expected to be approximately $201.8 million, before deducting the underwriting discounts and commissions and estimated offering expenses.

Morgan Stanley, BofA Merrill Lynch and Barclays acted as joint book-running managers. Raymond James acted as co-manager of the offering.

The company has 33.43M of outstanding shares and 26.16M shares were floated in the market. According to the most recent quarter its current ratio was 17.7 that represents company’s ability to meet its current financial obligations. The price moved ahead of -7.63% from the mean of 20 days, -4.77% from 50 and performed 57.44% from 200 days average price. Company’s performance for the week was -7.20%, -12.52% for month and yearly performance remained 215.11%.

Leave a Reply

Your email address will not be published. Required fields are marked *